Cynata Therapeutics Takes Fresh Approach to Stem Cell Production

Video

Ross Macdonald, PhD, managing director and CEO of Cynata Therapeutics, discusses the biotech company's approach to overcoming reproducibility challenges with mesenchymal stem cells.

Much like the manufacturing challenges that plague the gene therapy space, biotechnology companies focused on stem cell and regenerative therapies often find themselves faced with reproducibility issues that can compromise the quality of the end product.

Derived from donated tissue, current industry-standard manufacturing processes that rely upon cell reproduction within cell cultures are self-limiting.

"Excessive culture, prior to utilization as a therapy in therapeutic purposes, causes the cells to undergo what's called senescence, and they are no longer as potent or as efficient as they were when they were freshly isolated," said Ross Macdonald, PhD, managing director and chief executive officer, Cynata Therapeutics.

To surpass these limitations, Macdonald and the Cynata team have developed a novel manufacturing platform, called Cymerus, that utilizes mesenchymoangioblasts derived from induced pluripotent stem cells.

In an interview with GeneTherapyLive, Macdonald expanded on the advantages of the Cymerus platform and why their novel process can address several limitations of current industry standards.

Recent Videos
Caroline Diorio, MD, FRCPC, FAAP, an attending physician at the Cancer Center at Children's Hospital of Philadelphia
R. Nolan Townsend; Sandi See Tai, MD; Kim G. Johnson, MD
Daniela van Eickels, MD, PhD, MPH, the vice president and head of medical affairs for Bristol Myers Squibb’s Cell Therapy Organization
Paul Melmeyer, MPP, the executive vice president of public policy & advocacy at MDA
Daniela van Eickels, MD, PhD, MPH, the vice president and head of medical affairs for Bristol Myers Squibb’s Cell Therapy Organization
Arun Upadhyay, PhD, the chief scientific officer and head of research, development, and Medical at Ocugen
Arun Upadhyay, PhD, the chief scientific officer and head of research, development, and Medical at Ocugen
John Brandsema, MD, a pediatric neurologist in the Division of Neurology at Children’s Hospital of Philadelphia
John Brandsema, MD, a pediatric neurologist in the Division of Neurology at Children’s Hospital of Philadelphia
Related Content
© 2024 MJH Life Sciences

All rights reserved.